PTK2 and neoplasm: Another FAK inhibitor, PF-00562271, reduces tumor growth, metastases, and ameliorates tumor microenvironment when used in an orthotopic mouse model for pancreatic cancer (Stokes et al., 2011), suggesting this drug could be promising for pancreatic cancer patients.